The Nagalase Test
Nagalase is short for "alpha-N-acetylgalactosaminidase"
Nagalase is an enzyme that suppresses your immune system. (1) (2) (4) (5)What do Chronic Fatigue Syndrome, Cancer, AIDs, Autism & Lupus have in common?
• Viruses (like Influenza, HIV, Epstein-Barr and herpes zoster) secrete Nagalase. (1) (2) (9)• Cancer cells secrete Nagalase. (3) (4) (5)
• Of 400 Autistic Children tested, 80% of them had high Nagalase. (6)
• Chronic Fatigue is an immune system dysfunction, often with evidence of viral persistence. (7)
• 33 x Systemic Lupus Erythematosus patients were found to have high Nagalase. (8)
High Nagalase indicates that your condition can be successfully treated with GcMAF.
For a list of NZ Doctors who treat high Nagalase with GcMAF go to our Doctors Page.
Book Your Nagalase Test.
We organise the Nagalase Test in New Zealand.The cost is $350.
Blood is drawn by the "Diagnostic Medlab", at 10 Harrison Road in Ellerslie, Auckland.
Samples are frozen at -35°C and batched before transport to the Netherlands for testing.
The next batch opens on Monday the 23rd of January 2012, and closes on Friday the 2nd of March 2012 at 4pm. Blood must be drawn between these dates to be included in the next batch.
Note: All patient information is held in strict confidence.
Note:
After booking your test, you will be taken to a page with instructions for making a deposit of $250 to cover freight and the Netherlands Lab.
After we have received your deposit, we will send you a "Nagalase Test Authorisation Form" to take to the Diagnostic Medlab at 10 Harrison Road, Ellerslie, Auckland. You can turn up anytime with the "Form" between the hours of 8AM to 4PM, Monday to Friday.
The final payment of $100 is made to the Diagnostic Medlab at the time of the blood being drawn.
Currently we are aware that an intake of GcMAF, Niclosamide or Hydroxocobalamin, within five days of the blood draw interferes with the Nagalase Test results.
References:
(1) Yamamoto N, Urade M.
Pathogenic significance of alpha-N-acetylgalactosaminidase activity found in the hemagglutinin of influenza virus.
Microbes Infect. 2005 Apr;7(4):674-81. Epub 2005 Mar 22. Link to Abstract
(2) Yamamoto N.
Pathogenic significance of alpha-N-acetylgalactosaminidase activity found in the envelope glycoprotein gp160 of human immunodeficiency virus Type 1.
AIDS Res Hum Retroviruses. 2006 Mar;22(3):262-71. Link to Abstract
(3) Korbelik M, Naraparaju VR, Yamamoto N.
The value of serum alpha-N-acetylgalactosaminidase measurement for the assessment of tumour response to radio- and photodynamic therapy.
Br J Cancer. 1998 Mar;77(6):1009-14. Link to Abstract
(4) Yamamoto N, Naraparaju VR, Urade M.
Prognostic utility of serum alpha-N-acetylgalactosaminidase and immunosuppression resulted from deglycosylation of serum Gc protein in oral cancer patients.
Cancer Res. 1997 Jan 15;57(2):295-9. Link to Abstract
(5) Yamamoto N, Naraparaju VR, Asbell SO.
Deglycosylation of serum vitamin D3-binding protein leads to immunosuppression in cancer patients.
Cancer Res. 1996 Jun 15;56(12):2827-31. Link to Abstract
(6) Dr Jeff Bradstreet, MD, MD(H), FAAFP.
An Update on Viral Issue in Autism.
http://drbradstreet.org/category/autism/ (Retrieved 22/10/2011) Link to Webpage
(7) Bansal AS, Bradley AS, Bishop KN, Kiani-Alikhan S, Ford B.
Chronic fatigue syndrome, the immune system and viral infection.
Brain Behav Immun. 2011 Jul 2. [Epub ahead of print] Link to Abstract
(8) Yamamoto N, Naraparaju VR, Moore M, Brent LH.
Deglycosylation of serum vitamin D3-binding protein by alpha-N-acetylgalactosaminidase detected in the plasma of patients with systemic lupus erythematosus.
Clin Immunol Immunopathol. 1997 Mar;82(3):290-8. Link to Abstract
(9) Yamamoto, Nobuto (Philadelphia, PA)
Preparation of potent macrophage activating factors derived from cloned vitamin D binding protein and its domain and their therapeutic usage for cancer, HIV-infection and osteopetrosis.
United States Patent 6410269. Link to Patent